Safety and Efficacy of Allogeneic Lung Spheroid Cells in a Mismatched Rat Model of Pulmonary Fibrosis

Autor: Jianhua Liu, Phuong-Uyen Dinh, Tyler A. Allen, Leonard J. Lobo, M. Taylor Hensley, S. Michaela Rikard, Yazhou Li, Yuepeng Chi, Junnan Tang, Kathryn Kinlaw, Dipti Paudel, Ke Cheng, Bo Niu, Adam C. Vandergriff, Thomas G. Caranasos, Jhon Cores
Rok vydání: 2017
Předmět:
0301 basic medicine
Pathology
medicine.medical_specialty
Pulmonary Fibrosis
medicine.medical_treatment
Stem cells
Bleomycin
03 medical and health sciences
Idiopathic pulmonary fibrosis
Translational Research Articles and Reviews
Fibrosis
Tissue Engineering and Regenerative Medicine
Spheroids
Cellular
Pulmonary fibrosis
Animals
Transplantation
Homologous
Medicine
Rats
Wistar
Bronchopulmonary Disorders
Lung
Allogeneic
Cells
Cultured
Clinical Application / Translation
business.industry
Mesenchymal stem cell
Interstitial lung disease
Pulmonary
Cell Biology
General Medicine
Stem-cell therapy
Syngeneic
medicine.disease
Rats
Adult Stem Cells
Wound Healing / Fibrosis
030104 developmental biology
medicine.anatomical_structure
Lung Stem Cells
Female
Stem cell
business
Stem Cell Transplantation
Developmental Biology
Zdroj: Stem Cells Translational Medicine
ISSN: 2157-6580
2157-6564
DOI: 10.1002/sctm.16-0374
Popis: Idiopathic pulmonary fibrosis is a devastating interstitial lung disease characterized by the relentless deposition of extracellular matrix causing lung distortions and dysfunctions. The prognosis after detection is merely 3–5 years and the only two Food and Drug Administration-approved drugs treat the symptoms, not the disease, and have numerous side effects. Stem cell therapy is a promising treatment strategy for pulmonary fibrosis. Current animal and clinical studies focus on the use of adipose or bone marrow-derived mesenchymal stem cells. We, instead, have established adult lung spheroid cells (LSCs) as an intrinsic source of therapeutic lung stem cells. In the present study, we compared the efficacy and safety of syngeneic and allogeneic LSCs in immuno-competent rats with bleomycin-induced pulmonary inflammation in an effort to mitigate fibrosis development. We found that infusion of allogeneic LSCs reduces the progression of inflammation and fibrotic manifestation and preserves epithelial and endothelial health without eliciting significant immune rejection. Our study sheds light on potential future developments of LSCs as an allogeneic cell therapy for humans with pulmonary fibrosis.
Databáze: OpenAIRE
Externí odkaz: